vs
CORE MOLDING TECHNOLOGIES INC（CMT）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
CORE MOLDING TECHNOLOGIES INC的季度营收约是RIGEL PHARMACEUTICALS INC的1.1倍（$74.7M vs $69.8M），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs 19.5%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs -2.2%）
科模成型技术公司1988年成立，总部位于美国俄亥俄州哥伦布市，主要生产片状模塑料以及模压玻纤增强塑料，生产总面积超100万平方英尺，在墨西哥马塔莫罗斯、美国南卡罗来纳州加夫尼、俄亥俄州辛辛那提设有主要分支机构，2011年成立了子公司科瑞特种复合材料有限公司。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
CMT vs RIGL — 直观对比
营收规模更大
CMT
是对方的1.1倍
$69.8M
营收增速更快
RIGL
高出1.7%
19.5%
两年增速更快
RIGL
近两年复合增速
-2.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $74.7M | $69.8M |
| 净利润 | — | $268.1M |
| 毛利率 | 15.2% | 91.5% |
| 营业利润率 | 4.8% | 33.2% |
| 净利率 | — | 384.0% |
| 营收同比 | 19.5% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $0.35 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMTRIGL
| Q4 25 | $74.7M | $69.8M | ||
| Q3 25 | $58.4M | $69.5M | ||
| Q2 25 | $79.2M | $101.7M | ||
| Q1 25 | $61.4M | $53.3M | ||
| Q4 24 | $62.5M | $57.6M | ||
| Q3 24 | $73.0M | $55.3M | ||
| Q2 24 | $88.7M | $36.8M | ||
| Q1 24 | $78.1M | $29.5M |
净利润CMTRIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $1.9M | $27.9M | ||
| Q2 25 | $4.1M | $59.6M | ||
| Q1 25 | $2.2M | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $3.2M | $12.4M | ||
| Q2 24 | $6.4M | $-1.0M | ||
| Q1 24 | $3.8M | $-8.2M |
毛利率CMTRIGL
| Q4 25 | 15.2% | 91.5% | ||
| Q3 25 | 17.4% | 93.2% | ||
| Q2 25 | 18.1% | 95.6% | ||
| Q1 25 | 19.2% | 91.7% | ||
| Q4 24 | 15.8% | 89.9% | ||
| Q3 24 | 16.9% | 85.5% | ||
| Q2 24 | 20.0% | 92.4% | ||
| Q1 24 | 17.0% | 93.1% |
营业利润率CMTRIGL
| Q4 25 | 4.8% | 33.2% | ||
| Q3 25 | 4.4% | 40.9% | ||
| Q2 25 | 6.6% | 60.1% | ||
| Q1 25 | 4.6% | 23.9% | ||
| Q4 24 | 1.4% | 28.9% | ||
| Q3 24 | 4.9% | 25.4% | ||
| Q2 24 | 8.4% | 1.2% | ||
| Q1 24 | 6.1% | -23.6% |
净利率CMTRIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | 3.2% | 40.2% | ||
| Q2 25 | 5.1% | 58.6% | ||
| Q1 25 | 3.6% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | 4.3% | 22.5% | ||
| Q2 24 | 7.2% | -2.8% | ||
| Q1 24 | 4.8% | -27.9% |
每股收益（稀释后）CMTRIGL
| Q4 25 | $0.35 | $14.11 | ||
| Q3 25 | $0.22 | $1.46 | ||
| Q2 25 | $0.47 | $3.28 | ||
| Q1 25 | $0.25 | $0.63 | ||
| Q4 24 | $-0.01 | $0.82 | ||
| Q3 24 | $0.36 | $0.70 | ||
| Q2 24 | $0.73 | $-0.06 | ||
| Q1 24 | $0.43 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $38.1M | $155.0M |
| 总债务越低越好 | $17.6M | $52.5M |
| 股东权益账面价值 | $158.2M | $391.5M |
| 总资产 | $228.1M | $513.6M |
| 负债/权益比越低杠杆越低 | 0.11× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资CMTRIGL
| Q4 25 | $38.1M | $155.0M | ||
| Q3 25 | $42.4M | $137.1M | ||
| Q2 25 | $43.2M | $108.4M | ||
| Q1 25 | $44.5M | $77.1M | ||
| Q4 24 | $41.8M | $77.3M | ||
| Q3 24 | $42.3M | $61.1M | ||
| Q2 24 | $37.8M | $49.1M | ||
| Q1 24 | $26.6M | $49.5M |
总债务CMTRIGL
| Q4 25 | $17.6M | $52.5M | ||
| Q3 25 | $18.2M | $60.0M | ||
| Q2 25 | $18.8M | $60.0M | ||
| Q1 25 | $19.2M | $60.0M | ||
| Q4 24 | $19.7M | $60.0M | ||
| Q3 24 | $20.2M | $60.0M | ||
| Q2 24 | $20.6M | $60.0M | ||
| Q1 24 | $21.1M | $60.0M |
股东权益CMTRIGL
| Q4 25 | $158.2M | $391.5M | ||
| Q3 25 | $155.4M | $117.6M | ||
| Q2 25 | $153.5M | $81.9M | ||
| Q1 25 | $149.9M | $18.6M | ||
| Q4 24 | $147.4M | $3.3M | ||
| Q3 24 | $147.8M | $-14.6M | ||
| Q2 24 | $147.5M | $-29.9M | ||
| Q1 24 | $142.8M | $-31.7M |
总资产CMTRIGL
| Q4 25 | $228.1M | $513.6M | ||
| Q3 25 | $219.7M | $242.5M | ||
| Q2 25 | $219.9M | $206.7M | ||
| Q1 25 | $223.6M | $176.0M | ||
| Q4 24 | $209.6M | $164.0M | ||
| Q3 24 | $220.7M | $139.4M | ||
| Q2 24 | $225.7M | $128.4M | ||
| Q1 24 | $212.3M | $126.5M |
负债/权益比CMTRIGL
| Q4 25 | 0.11× | 0.13× | ||
| Q3 25 | 0.12× | 0.51× | ||
| Q2 25 | 0.12× | 0.73× | ||
| Q1 25 | 0.13× | 3.23× | ||
| Q4 24 | 0.13× | 18.25× | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.14× | — | ||
| Q1 24 | 0.15× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.0M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $-2.9M | — |
| 自由现金流率自由现金流/营收 | -3.9% | — |
| 资本支出强度资本支出/营收 | 10.7% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $1.9M | — |
8季度趋势，按日历期对齐
经营现金流CMTRIGL
| Q4 25 | $5.0M | $22.0M | ||
| Q3 25 | $4.6M | $24.0M | ||
| Q2 25 | $3.5M | $30.5M | ||
| Q1 25 | $6.1M | $-893.0K | ||
| Q4 24 | $5.0M | $14.5M | ||
| Q3 24 | $9.2M | $21.7M | ||
| Q2 24 | $15.9M | $302.0K | ||
| Q1 24 | $5.1M | $-5.0M |
自由现金流CMTRIGL
| Q4 25 | $-2.9M | — | ||
| Q3 25 | $-346.0K | — | ||
| Q2 25 | $880.0K | — | ||
| Q1 25 | $4.3M | — | ||
| Q4 24 | $509.0K | — | ||
| Q3 24 | $7.0M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $3.2M | — |
自由现金流率CMTRIGL
| Q4 25 | -3.9% | — | ||
| Q3 25 | -0.6% | — | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 7.0% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 9.6% | — | ||
| Q2 24 | 14.6% | — | ||
| Q1 24 | 4.1% | — |
资本支出强度CMTRIGL
| Q4 25 | 10.7% | — | ||
| Q3 25 | 8.4% | — | ||
| Q2 25 | 3.3% | — | ||
| Q1 25 | 2.9% | — | ||
| Q4 24 | 7.2% | — | ||
| Q3 24 | 3.1% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 2.4% | — |
现金转化率CMTRIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 2.44× | 0.86× | ||
| Q2 25 | 0.86× | 0.51× | ||
| Q1 25 | 2.79× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | 2.92× | 1.75× | ||
| Q2 24 | 2.47× | — | ||
| Q1 24 | 1.35× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
